Clinical Trials Browser

Phase 2 × Recurrence × Hematopoietic Stem Cell Mobilization × Clear all

NCT03618550 2025-12-02

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Phase 2 Recruiting

Hodgkin Disease, Recurrence